Microbot Medical Inc

Microbot Medical Inc

Health CareMedical Equipment and Services
  • Price (USD)5.05
  • Today's Change0.17 / 3.48%
  • Shares traded19.31k
  • 1 Year change-30.92%
  • Beta4.2880
Data delayed at least 15 minutes, as of Dec 08 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms are comprised of ViRob, TipCAT and Liberty, including certain CardioSert assets. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. TipCAT is a disposable self-propelled locomotive device, designed to advance in tubular anatomies. Liberty is a disposable robotic system, designed to move guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.09m
  • Incorporated1988
  • Employees12.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Arca Biopharma Inc0.00-18.77m33.29m11.00--0.5881-----1.54-1.540.003.930.00----0.00-33.47-59.66-34.93-65.51------------0.00-------77.64--11.55--
BioCardia Inc982.00k-12.15m33.32m24.00--2.48--33.93-0.7671-0.76710.06140.7950.0732--3.9140,916.67-90.57-97.01-130.70-118.62100.008.68-1,237.37-2,616.10----0.00---79.58-30.65-2.01------
Greenlink International Inc1.32m-1.00m33.57m10.00------25.46-0.0031-0.00310.0041-0.0071.1940.4128.46---90.30-70.66----0.424719.02-76.05-26.760.0653-8.92-----30.19-12.0224.15------
Aridis Pharmaceuticals Inc548.00k-43.33m34.01m33.00------62.06-3.78-3.780.05-0.29560.0287--0.798816,606.06-205.32-90.77---145.41-----7,154.38-1,355.55---------2.15-18.9724.76--225.79--
Soligenix Inc869.40k-13.39m34.10m17.00--2.25--39.22-0.3842-0.38420.02360.35310.0405--3.9651,141.18-62.31-89.59-82.04-163.4115.5319.15-1,539.84-164.83---20.390.3954---49.04-23.09-89.07---20.20--
Navidea Biopharmaceuticals Inc700.42k-11.08m34.11m13.00--10.02--48.70-0.3908-0.39080.02460.11280.0937--1.5153,878.46-145.79-105.66-405.14--100.0098.21-1,556.48-618.751.83-1,905.220.00--39.10-41.41-4.02--44.33--
Weed Inc0.00-2.58m34.46m2.00--43.04-----0.0224-0.02240.000.00680.00----0.00-136.03-952.22-286.34-1,565.31-----------63.310.3174------85.23------
Alimera Sciences Inc58.84m-1.24m34.55m130.00----25.840.5872-0.3918-0.39189.250.21681.082.933.70452,646.20-2.28-29.58-2.84-38.3088.0189.32-2.11-39.413.630.54480.9663---5.7917.7648.87--6.57--
Microbot Medical Inc0.00-10.09m34.69m12.00--1.94-----1.42-1.420.002.510.00----0.00-42.29-57.64-44.44-68.96-----------228.340.00-------26.52--114.59--
Liminal BioSciences Inc1.14m-62.37m34.77m251.00--0.7515--30.51-2.19-0.35970.03891.490.01070.08872.054,539.53-59.44-84.06-66.80-105.5740.9746.35-5,533.61-935.816.21--0.5696---32.36-32.9847.98---21.64--
Acura Pharmaceuticals, Inc.2.25m-1.15m35.15m14.00--260.36--15.66-0.028-0.0280.0490.00211.25--23.88---63.8617.52-159.8643.34-----51.2733.48---3.550.7059--34.36-16.1067.99------
Trinity Biotech plc (ADR)116.22m-1.51m35.53m543.00----22.600.3058-0.072-0.095.56-0.02060.91711.877.17214,025.80-1.19-13.81-2.41-15.5246.7943.74-1.30-27.480.44273.731.01--12.770.353879.26---17.44--
Cyclacel Pharmaceuticals Inc0.00-20.37m35.61m12.00--0.8456-----3.42-3.420.004.220.00-------45.41-38.38-49.01-46.95-------4,312.59----0.00-------54.66--23.07--
Galera Therapeutics Inc0.00-83.79m35.96m38.00---------3.29-3.290.00-1.630.00----0.00-85.14---98.23-------------12.981.52-------25.57------
Aditxt Inc0.00-27.00m35.98m43.00--1.54-----1.83-1.830.000.53840.00----0.00-154.49---176.48-------------11.990.00-------56.99------
Data as of Dec 08 2021. Currency figures normalised to Microbot Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

10.67%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2021266.45k3.75%
BlackRock Fund Advisorsas of 30 Sep 2021153.60k2.16%
Contego Capital Group, Inc.as of 30 Sep 2021100.00k1.41%
Dimensional Fund Advisors LPas of 30 Sep 202195.06k1.34%
Geode Capital Management LLCas of 30 Sep 202150.50k0.71%
SSgA Funds Management, Inc.as of 30 Sep 202134.77k0.49%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 202119.04k0.27%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Sep 202115.60k0.22%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202111.88k0.17%
Steward Partners Investment Advisory LLCas of 30 Sep 202111.60k0.16%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.